GSA Capital Partners LLP Purchases 354,474 Shares of Cardlytics, Inc. (NASDAQ:CDLX)

GSA Capital Partners LLP grew its position in Cardlytics, Inc. (NASDAQ:CDLX) by 1,273.2% in the third quarter, HoldingsChannel.com reports. The fund owned 382,315 shares of the company’s stock after buying an additional 354,474 shares during the period. GSA Capital Partners LLP’s holdings in Cardlytics were worth $1,223,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Canton Hathaway LLC grew its position in shares of Cardlytics by 95.7% in the 2nd quarter. Canton Hathaway LLC now owns 4,500 shares of the company’s stock valued at $37,000 after acquiring an additional 2,200 shares during the period. XTX Topco Ltd bought a new position in shares of Cardlytics in the 2nd quarter valued at about $107,000. Banco Santander S.A. bought a new position in shares of Cardlytics in the 1st quarter valued at about $199,000. SG Americas Securities LLC bought a new position in shares of Cardlytics in the 3rd quarter valued at about $45,000. Finally, Quest Partners LLC grew its position in shares of Cardlytics by 160.4% in the 2nd quarter. Quest Partners LLC now owns 17,956 shares of the company’s stock valued at $147,000 after acquiring an additional 11,061 shares during the period. Institutional investors own 68.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on CDLX shares. Lake Street Capital cut shares of Cardlytics from a “buy” rating to a “hold” rating and cut their target price for the stock from $18.00 to $5.00 in a research note on Thursday, August 8th. Northland Capmk cut shares of Cardlytics from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 16th. Craig Hallum upgraded shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 6th. Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and cut their target price for the stock from $4.00 to $3.50 in a research note on Thursday, August 15th. Finally, Evercore ISI started coverage on shares of Cardlytics in a research note on Friday, October 11th. They set an “in-line” rating and a $4.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Cardlytics has a consensus rating of “Hold” and an average price target of $6.92.

Cardlytics Price Performance

Shares of Cardlytics stock opened at $3.60 on Friday. Cardlytics, Inc. has a twelve month low of $2.89 and a twelve month high of $20.52. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. The company has a 50-day simple moving average of $3.73 and a two-hundred day simple moving average of $6.48. The stock has a market capitalization of $182.70 million, a price-to-earnings ratio of -0.59 and a beta of 1.61.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.18. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The business had revenue of $67.06 million during the quarter, compared to analysts’ expectations of $57.77 million. During the same quarter in the previous year, the company earned ($0.26) EPS. The business’s revenue was down 15.1% on a year-over-year basis. Analysts forecast that Cardlytics, Inc. will post -1.72 EPS for the current year.

Insider Buying and Selling at Cardlytics

In other Cardlytics news, CEO Amit Gupta sold 22,607 shares of the firm’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the transaction, the chief executive officer now directly owns 178,519 shares of the company’s stock, valued at $687,298.15. This trade represents a 11.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 43,573 shares of company stock valued at $151,612 in the last ninety days. 4.40% of the stock is currently owned by company insiders.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.